Objectives: Omalizumab is a humanised anti-IgE recombinant monoclonal antibody approved in Turkey for treatment of chronic idiopathic (or spontaneous) urticaria (CIU) in patients resistant to standard treatment. We aimed to assess the cost-effectiveness of omalizumab compared with the standard care in the treatment of CIU patients in Turkey. MethOds: A Markov model of 10 years horizon was developed to estimate costs and outcomes associated with omalizumab 300mg/every 4 weeks and standard of care for 24 weeks (SoC= licensed dose H1 antihistamines) using data from two phase III studies (ASTERIA I&II includes patients with CIU refractory to licensed dose of H1-antihistamines). The study was undertaken from a Turkish health care payer perspective. At the end of this period, omalizumab was stopped and background medication continued. Patients who have responded were retreated by the same strategy upon relapse (UAS7 ≥ 16 or ≥ 28). We used Urticaria Activity Score 7 (UAS7) to measure the outcome of the treatment and we used symptom free days (UAS7 ≤ 6) as the outcome measure in this cost effectiveness analysis. Resource utilization data were obtained via a Delphi panel. Unit costs were taken from the Social Security Institution's official list. Costs and outcomes were evaluated over a lifetime and discounted at 3%. Results were presented as incremental cost/symptom free days. Results: The incremental symptom free days with omalizumab versus SoC was 27,965 days and the incremental cost was 1,610,349 Turkish Liras for 100 patients over 10 years. The incremental cost per symptom free day was 57.59 Turkish Liras. One-way sensitivity analyses confirmed the robustness of the model results. cOnclusiOns: CIU affects the quality of life of patients and is associated with direct and indirect costs to payers and society. We believe that omalizumab 300mg Q4wks is a cost-effective treatment option for patients with refractory CIU in Turkish setting. Objectives: To evaluate the efficacy of treatment with ranibizumab in a sample of Greek patients with nAMD. MethOds: In this observational, non-interventional, retrospective study, 194 cases with nAMD were enrolled from the Ophthalmology Department of "Attikon" hospital. Patients treated with ranibizumab for at least one year in one eye under routine clinical practice, and had at least one follow-up visit, were considered eligible. Patients participating in another study and/or were receiving pharmaceutical product containing VEGF inhibitors were excluded. Primary endpoints were the mean change in Best Corrected Visual Acuity (BCVA), and in Central retinal thickness (CRT), assessed by Optical Coherence Tomography. Results: The average BCVA score per eye at baseline was 0.284 in decimal points (Snellen equivalent≈ 20/84; ETDRS letters≈ 57.7), which improved at final visit (≈14 months after baseline) reaching 0.336 (Snellen equivalent≈ 20/60; ETDRS letters≈ 61.3), i.e. 6,33% or approximately 3.7 ETDRS letters improvement (p< 0.001, r= 0.317) with 4.9 ranibizumab injections overall (4.3 injections/year). CRT similarly improved, as it decreased by 28.4%, from 290.31 to 207.77 μ m (p< 0.001, r= 0.683). An extra ranibizumab injection per eye per year, increased the odds of an at least 0.1 increase in BCVA from baseline to last visit by 20.8% (95%CI 1.068-1.366), and an at least 0.2 increase by 15.7% (95%CI 1.013-1.322). cOnclusiOns: Ranibizumab provides significant benefit in patients with nAMD under routine clinical practice by improving BCVA and reducing CRT, benefit which may be more important in a more frequent dosing regimen. Objectives: Background: The project focused on the preventive use, effectiveness and the better knowledge about the potential effects and mechanisms of dressings. Aims: To improve the effectiveness of wound care, to prevent effectively the appearance of pressure ulcers during hospitalization. MethOds: During 2 months of the project 80 patients of 3 active and 2 chronic care departments were involved, treatment of 84 pressure ulcers of 46 patients occurred. After the health check the attachment of dressings and the wound management were carried out according to the protocols and were documented on special datasheets. Subsequently, the checking and processing of questionnaires -continuing the monitoring of patient pathways -were done. Results: Pressure ulcers did not develop in case of 79% of the patients after prevention, effectiveness of targeted prevention reached 95.5%. The incidence of decubitus fell by 1.6-1.7 % in the project (formation rate was 58.8-90.9 % lower in average). In the background of successful prevention min. 3-day use was observed, but even use of 1-1 preventive dressing was effective. The average length of wound care was14 days, frequency was 8.2 times/patient. The healed or recovering wounds were more frequently treated, but rather for more days, however, their treatment cost less than the average and those wounds which were not healing. cOnclusiOns: Wound care starts with prevention. The quality of wound care should not decrease after the patient's discharge, the home follow-up would be essential, nevertheless its "best practices" has not spread widely in Hungary yet. In the short term Decubitus Team doctors should be involved in patients' discharge planning, however in the long term creation of a so-called Wound Care Centre could offer a sustainable solution. Hereinafter controlled trials of higher number of cases could prove the cost-effectiveness of intelligent dressings in wider aspects of the health care system. tobacco tax is important as a source of revenue. The objectives of this research is to quantitatively assess about how general public value several aims of tobacco policy and the amount of tax revenue and to estimate "ideal" tobacco price where the price elasticity of tobacco consumption is given. MethOds: We conducted a web-based survey from 9-15, Aug 2012 including a discrete choice experiment (DCE) to elicit general public's preference for targeted smoking rate, tax revenue, tobacco policy for the younger generation and the usage of tax. Then, we numerically forecast general publics' support rate of a tobacco policy as a function of tobacco price where price elasticity is given. Results: 1,077 completed questionnaires and were eligible for analysis. They statistically prefer the tobacco policy which results in lower prevalence of smokers, higher tax revenue, targeted for young people and tax revenue is used for general purposes. Given the price elasticity of 0.3, 0.4 and 0.5, highest tobacco price, which acquire the highest support from general public, was around JPY871 (EUR6.2), JPY555 (EUR4.0) and JPY454 (EUR3.2), respectively. cOnclusiOns: The present price of cigarette per one pack is around JPY460 (EUR 3.3) . When smokers are highly responsive to price elevation and are successfully quit after the elevation, present price of cigarette is suitable when we consider public's preference for tax revenue as well as normal policy measures. Rooms for further price elevations depends on the price elasticity of cigarette consumption.
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Objectives: To indirectly compare the efficacy of approved treatments for macular oedema secondary to branch retinal vein occlusion (BRVO). MethOds: Randomized, controlled trials (RCTs) evaluating the efficacy at month 6 (or month 12) of at least two of ranibizumab 0.5mg pro re nata (after 6 monthly doses), aflibercept 2.0mg monthly, dexamethasone implant (retreatment interval ≥ 6 months), laser photocoagulation or sham were identified from a published systematic review, congress abstracts, clinicaltrials. gov and Novartis data on file. Outcomes of interest were the mean change in best-corrected visual acuity (BCVA, measured as Early Treatment Diabetic Retinopathy Study letters), and the percentage of patients gaining ≥ 15 letters. For two studies, the standard deviation around mean BCVA gain was estimated. A Bayesian network meta-analysis with random treatment effects was used to compare mean BCVA gains and odds ratios (ORs) for gaining ≥ 15 letters. Results: The analysis included seven RCTs. Patient-level data for three ranibizumab trials were re-analysed to match key inclusion criteria (BCVA and duration of disease at baseline) from aflibercept studies. Statistically significant (p< 0.05) BCVA letter gains were found for ranibizumab monotherapy (+11.6), ranibizumab plus laser combination therapy (+10.1) and aflibercept (+10.1) versus laser, and for ranibizumab monotherapy versus dexamethasone (+8.0). ORs versus laser for gaining ≥ 15 letters were 3.24 (95% credible interval, 1.03-12.56; p< 0.05) and 3.07 (0.63-14.8) for ranibizumab monotherapy and aflibercept, respectively. Mean BCVA letter gains were numerically higher with ranibizumab monotherapy compared with aflibercept (+1.5 letters [-5.3-8.8 ]; OR for gaining ≥ 15 letters, 1.06 [0.16-8.94] ). The probability of being the most efficacious treatment based on letters gained was 57% for ranibizumab, 15% for ranibizumab plus laser and 28% for aflibercept. cOnclusiOns: The analysis confirms the superiority of ranibizumab over dexamethasone implant and laser therapy, and shows that ranibizumab has the highest likelihood of being the most efficacious treatment for BRVO. Objectives: Recently, advanced treatments such as topical growth factors, biological dressings, and tissue engineered products have been developed in order to promote healing as well as decrease the time to healing of chronic leg ulcers. Nevertheless, if standard care fails, there is no widely accepted, easy to use secondline treatment primarily because most of these advanced treatments are expensive and need further evidence of effectiveness in everyday clinical practice. The purpose of our study was to assess the effectiveness of a new acellular synthetic matrix (ASM) as an adjunct to standard care, using healing time as endpoint, in venous and mixed leg ulcers in German everyday clinical practice. MethOds: Prospective data on venous and mixed leg ulcers from a safety and effectiveness study on an acellular synthetic matrix was compared retrospectively to matched data from a German Registry of Chronic Wounds (DRCW) database containing German patients with equivalent leg ulcer disease, patient age and gender, baseline wound area, wound duration, same outcome measures, and comparable follow-up periods. The outcome of interest was healing time over 12-weeks of treatment. Results: Analysis using Kaplan Meier survival curves showed a mean of 73.1 days (95% CI: 66.4 -79.9 days) to healing for acellular synthetic matrix treated ulcers, in comparison to 92.2 days (95% CI: 87.1 -97.2 days) for equivalent ulcers treated in everyday clinical practice in Germany (Log rank test χ 2 11.46, p= 0.001). cOnclusiOns: Results from this study predict a highly significant effect of a new acellular synthetic matrix as an adjunct to standard care in the repair of venous and mixed leg ulcers. The predictive model may be useful in determining expected effectiveness of the acellular synthetic matrix in the treatment of venous and mixed leg ulcer patients treated in everyday clinical practice in Germany.
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